Inflammatory biomarkers and cognitive functioning in individuals with euthymic bipolar disorder: exploratory study.
Inflammation
biomarker
bipolar affective disorder
cognition
neurogenesis
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
09 Jul 2021
09 Jul 2021
Historique:
entrez:
31
8
2022
pubmed:
9
7
2021
medline:
9
7
2021
Statut:
epublish
Résumé
Neurobiological research frequently implicates inflammatory and neurogenic components with core aspects of bipolar disorder. Even in periods of symptom remission (euthymia), individuals with bipolar disorder experience cognitive impairments, which are increasingly being proposed as an outcome for interventions; identifying biomarkers associated with cognitive impairment in people with bipolar disorder could advance progress in this therapeutic field through identifying biological treatment targets. We aimed to identify proteomic biomarker correlates of cognitive impairment in individuals with euthymic bipolar disorder. Forty-four adults with a bipolar disorder diagnosis in euthymia underwent a battery of cognitive assessments and provided blood for biomarkers. We examined a comprehensive panel of inflammatory and trophic proteins as putative cross-sectional predictors of cognition, conceptualised according to recommended definitions of clinically significant cognitive impairment (binary construct) and global cognitive performance (continuous measure). A total of 48% of the sample met the criteria for cognitive impairment. Adjusting for potentially important covariates, regression analyses identified lower levels of three proteins as significantly and independently associated with cognitive deficits, according to both binary and continuous definitions (interleukin-7, vascular endothelial growth factor C and placental growth factor), and one positively correlated with (continuous) global cognitive performance (basic fibroblast growth factor). This study identifies four candidate markers of cognitive impairment in bipolar disorder, none of which have been previously compared with cognitive function in participants with bipolar disorder. Pending replication in larger samples and support from longitudinal studies, these markers could have implications for treating cognitive dysfunction in this patient population.
Sections du résumé
BACKGROUND
BACKGROUND
Neurobiological research frequently implicates inflammatory and neurogenic components with core aspects of bipolar disorder. Even in periods of symptom remission (euthymia), individuals with bipolar disorder experience cognitive impairments, which are increasingly being proposed as an outcome for interventions; identifying biomarkers associated with cognitive impairment in people with bipolar disorder could advance progress in this therapeutic field through identifying biological treatment targets.
AIMS
OBJECTIVE
We aimed to identify proteomic biomarker correlates of cognitive impairment in individuals with euthymic bipolar disorder.
METHOD
METHODS
Forty-four adults with a bipolar disorder diagnosis in euthymia underwent a battery of cognitive assessments and provided blood for biomarkers. We examined a comprehensive panel of inflammatory and trophic proteins as putative cross-sectional predictors of cognition, conceptualised according to recommended definitions of clinically significant cognitive impairment (binary construct) and global cognitive performance (continuous measure).
RESULTS
RESULTS
A total of 48% of the sample met the criteria for cognitive impairment. Adjusting for potentially important covariates, regression analyses identified lower levels of three proteins as significantly and independently associated with cognitive deficits, according to both binary and continuous definitions (interleukin-7, vascular endothelial growth factor C and placental growth factor), and one positively correlated with (continuous) global cognitive performance (basic fibroblast growth factor).
CONCLUSIONS
CONCLUSIONS
This study identifies four candidate markers of cognitive impairment in bipolar disorder, none of which have been previously compared with cognitive function in participants with bipolar disorder. Pending replication in larger samples and support from longitudinal studies, these markers could have implications for treating cognitive dysfunction in this patient population.
Identifiants
pubmed: 36043690
doi: 10.1192/bjo.2021.966
pii: S2056472421009662
pmc: PMC8281256
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e126Références
Front Aging Neurosci. 2014 Mar 07;6:30
pubmed: 24639647
Curr Opin Psychiatry. 2013 Jan;26(1):19-26
pubmed: 23196997
Br J Psychiatry. 1998 Jun;172:527-32
pubmed: 9828995
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Neurosci Lett. 2009 Mar 13;452(2):111-3
pubmed: 19383424
Brain Behav Immun. 2013 Oct;33:183-9
pubmed: 23911592
Trends Pharmacol Sci. 2019 Jul;40(7):482-494
pubmed: 31130220
J Affect Disord. 2019 Feb 15;245:679-685
pubmed: 30447566
J Affect Disord. 2019 Mar 1;246:42-51
pubmed: 30578945
Lancet Psychiatry. 2016 Dec;3(12):1147-1156
pubmed: 27838212
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
J Affect Disord. 2013 Jan 10;144(1-2):16-27
pubmed: 22749156
Clin Pract Epidemiol Ment Health. 2007 Jun 07;3:5
pubmed: 17555558
Physiol Rev. 2009 Apr;89(2):607-48
pubmed: 19342615
J Psychiatr Res. 2014 Sep;56:18-27
pubmed: 24862657
Bipolar Disord. 2020 May;22(3):213-215
pubmed: 31965658
FASEB J. 2009 Oct;23(10):3629-36
pubmed: 19546306
Hum Psychopharmacol. 2013 Mar;28(2):160-7
pubmed: 23532748
Alzheimers Dement. 2014 Feb;10(1 Suppl):S76-83
pubmed: 24529528
J Neurotrauma. 1997 Apr;14(4):191-200
pubmed: 9151768
Bipolar Disord. 2007 Sep;9(6):596-602
pubmed: 17845274
J Clin Psychiatry. 2010 Feb;71(2):138-49
pubmed: 19895780
Psychiatry Res. 2020 Feb;284:112669
pubmed: 31740217
Bipolar Disord. 2017 Dec;19(8):614-626
pubmed: 28895274
J Clin Med. 2020 Dec 02;9(12):
pubmed: 33276697
J Psychopharmacol. 2017 Sep;31(9):1137-1148
pubmed: 28858537
Br J Psychiatry. 2010 Jan;196(1):52-8
pubmed: 20044661
Curr Neuropharmacol. 2014 May;12(3):273-80
pubmed: 24851091
J Pharmacol Sci. 2003 Apr;91(4):267-70
pubmed: 12719654
Bipolar Disord. 2021 Mar;23(2):196-208
pubmed: 32583630
Eur Neuropsychopharmacol. 2016 Oct;26(10):1541-61
pubmed: 27593623
Psychother Psychosom. 2009;78(5):285-97
pubmed: 19602917
Trials. 2016 Jul 29;17:371
pubmed: 27472964
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
J Affect Disord. 2009 Aug;116(3):214-7
pubmed: 19251324
J Neurosci. 2005 Sep 28;25(39):8843-53
pubmed: 16192374
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:181-8
pubmed: 23876786
J Psychiatr Res. 2011 Feb;45(2):156-61
pubmed: 20541770
J Affect Disord. 2015 Dec 1;188:149-59
pubmed: 26363613
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Psychiatry Res Neuroimaging. 2019 Mar 30;285:64-66
pubmed: 30785023
Stroke. 2013 Dec;44(12):3516-21
pubmed: 24072001
Cytokine Growth Factor Rev. 2017 Oct;37:89-97
pubmed: 28599834
Front Psychiatry. 2018 Aug 23;9:386
pubmed: 30190686
Value Health. 2010 Dec;13(8):984-8
pubmed: 20667057
Am J Psychiatry. 1994 Aug;151(8):1132-6
pubmed: 8037246
J Psychiatr Res. 2018 Nov;106:31-37
pubmed: 30261412
Neuropsychologia. 2002;40(3):271-81
pubmed: 11684160
Br J Med Psychol. 1959;32(1):50-5
pubmed: 13638508
J Affect Disord. 2016 Nov 15;205:165-181
pubmed: 27449549
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):846-51
pubmed: 20382196
Neurobiol Learn Mem. 2015 May;121:20-9
pubmed: 25838119
Neural Plast. 2014;2014:360481
pubmed: 25313338
Bipolar Disord. 2008 Feb;10(1):95-100
pubmed: 18199246
Cell Death Dis. 2011 Jun 02;2:e167
pubmed: 21633390
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):892-894
pubmed: 32527838
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13632-7
pubmed: 14581618
Eur Arch Psychiatry Clin Neurosci. 2015 Sep;265(6):449-59
pubmed: 25214388
Front Immunol. 2017 Nov 06;8:1464
pubmed: 29163531
BJPsych Open. 2020 Oct 30;6(6):e133
pubmed: 33121561
Brain Behav Immun. 2014 Jan;35:70-6
pubmed: 24016864
Bipolar Disord. 2009 Sep;11(6):663-71
pubmed: 19689509
J Affect Disord. 2013 Sep 5;150(2):456-9
pubmed: 23684514